Systolic Blood Pressure and Incident Heart Failure in the Elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study
Overview
Authors
Affiliations
Background: The exact form of the association between systolic blood pressure (SBP) and heart failure (HF) risk in the elderly remains incompletely defined, especially in individuals not receiving antihypertensive drugs.
Objective: To examine the association between SBP and HF risk in the elderly.
Design: Competing-risks proportional hazards modelling of incident HF risk, using 10-year follow-up data from two NIH-sponsored cohort studies: the Cardiovascular Health Study (inception: 1989-90 and 1992-3) and the Health ABC Study (inception: 1997-8).
Setting: Community-based cohorts.
Participants: 4408 participants (age, 72.8 (4.9) years; 53.1% women, 81.7% white; 18.3% black) without prevalent HF and not receiving antihypertensive drugs at baseline.
Main Outcome Measures: Incident HF, defined as first adjudicated hospitalisation for HF.
Results: Over 10 years, 493 (11.2%) participants developed HF. Prehypertension (120-139 mm Hg), stage 1 (140-159 mm Hg), and stage 2 (≥160 mm Hg) hypertension were associated with escalating HF risk; HRs versus optimal SBP (<120 mm Hg) in competing-risks models controlling for clinical characteristics were 1.63 (95% CI 1.23 to 2.16; p=0.001), 2.21 (95% CI 1.65 to 2.96; p<0.001) and 2.60 (95% CI 1.85 to 3.64; p<0.001), respectively. Overall 255/493 (51.7%) HF events occurred in participants with SBP <140 mm Hg at baseline. Increasing SBP was associated with higher HF risk in women than in men; no race-SBP interaction was seen. In analyses with continuous SBP, HF risk had a continuous positive association with SBP to levels as low as 113 mm Hg in men and 112 mm Hg in women.
Conclusions: There is a continuous positive association between SBP and HF risk in the elderly for levels of SBP as low as <115 mm Hg; over half of incident HF events occur in individuals with SBP <140 mm Hg.
Sato Y, Yoshihisa A, Ohashi N, Takeishi R, Sekine T, Nishiura K Hypertens Res. 2025; .
PMID: 39833554 DOI: 10.1038/s41440-025-02102-5.
Zhang G, Shi R, Li X, Yan W, Xu H, Li Y Cardiovasc Diabetol. 2024; 23(1):375.
PMID: 39443983 PMC: 11515597. DOI: 10.1186/s12933-024-02472-z.
Changing the paradigm in heart failure: shifting from treatment to prevention.
Chang A, Liang Y, Girouard M, Bhatt A, Sandhu A, Sauer A Heart Fail Rev. 2024; 30(1):177-189.
PMID: 39441333 DOI: 10.1007/s10741-024-10454-2.
Noninvasive biometric monitoring technologies for patients with heart failure.
Arriola-Montenegro J, Mutirangura P, Akram H, Tsangaris A, Koukousaki D, Tschida M Heart Fail Rev. 2024; .
PMID: 39436486 DOI: 10.1007/s10741-024-10441-7.
Qiu W, Cai A, Nie Z, Wang J, Ou Y, Feng Y J Am Heart Assoc. 2024; 13(10):e033777.
PMID: 38726897 PMC: 11179797. DOI: 10.1161/JAHA.123.033777.